Nutriband Inc. NTRB Archives

TuesdayApr 15, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients. AVERSA technology can be incorporated into any transdermal patch. The company has a broad and expanding intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. Nutriband closed an $8.4 million financing round in April 2024 to support commercial development of AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch. In February 2025, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery to support…

MondayApr 14, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of patients Nutriband recently announced two significant partnerships poised to expand its manufacturing capabilities and market reach These partnerships, along with the company’s already existing alliances, align with Nutriband's core mission of developing transdermal pharmaceutical products Strategic alliances are vital to success in the pharmaceutical sector, where innovation, regulatory navigation and market access are complex and resource-intensive. Collaborations between biotech firms, research institutions and major pharmaceutical companies accelerate drug development, reduce costs and enhance the likelihood of regulatory approval. Nutriband (NASDAQ: NTRB), a company focused on…

FridayApr 11, 2025 8:50 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures Patent in Macao for AVERSA Abuse-Deterrent Technology

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has been granted a patent in Macao for its AVERSA™ abuse-deterrent transdermal technology. The patent, titled “Abuse and Misuse Deterrent Transdermal Systems,” was granted on Feb. 11 and recorded in Macao’s Official Bulletin on Mar. 5. This adds to Nutriband’s global IP portfolio, with coverage now spanning 46 countries and both SARs of China. AVERSA is designed to reduce abuse, diversion and accidental exposure of transdermal drugs like opioids. Nutriband is advancing development of AVERSA Fentanyl with partner Kindeva Drug Delivery, aiming to commercialize the world’s first abuse-deterrent fentanyl patch…

TuesdaySep 24, 2024 10:00 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more. To view the full press release, visit https://ibn.fm/PeqGN About Nutriband Inc.…

FridaySep 20, 2024 12:45 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product

Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, AVERSA(TM) Fentanyl, an abuse deterrent fentanyl patch. The company’s abuse-deterrent transdermal technology includes the utilization of a proprietary aversive agent coating that uses taste aversion as a means to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. According…

TuesdaySep 17, 2024 8:55 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports on Share Repurchase Program

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has authorized a share repurchase program to buy back up to $1 million of its common stock. According to the announcement, as of Sept. 16, 2024, the company had 11,106,185 shares of common stock outstanding. The company also reported that it is continuing to make progress on the development of AVERSA Fentanyl, with a target date of submitting a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2025. To view the full press release, visit https://ibn.fm/aLx8t About Nutriband Inc. Nutriband is primarily…

MondayJul 15, 2024 11:15 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Obtains Notice of Allowance for Key Trademark Identified as ‘Integral’ to Platform Technology

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registration covering the mark “AVERSA” after completing administrative processes. Nutriband's proprietary AVERSA(TM) abuse deterrent transdermal technology works to incorporate aversive agents into transdermal patches that make an experience unpleasant, thereby discouraging abuse of substances. This technology is especially significant for drugs such as fentanyl, which have a high potential for abuse. The company’s lead product under development is AVERSA Fentanyl. Nutriband is…

MondayJun 03, 2024 3:48 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q1 2024 Quarterly Report

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, is reporting its first-quarter 2024 revenues. According to the report, the company saw revenues of $408,532 while also strengthening its balance sheet with the completion of an $8.4 million private placement involving existing and new shareholders; shares for the placement were offered at $4 per share. Nutriband also reported a cash position of $8,347,739. In the report, the company observed that it been focused on using penetration pricing to gain a foothold. “Meanwhile in Q1, the company has made further advancements in its development of AVERSA, and it is maintaining…

FridayMay 31, 2024 2:15 pm

QualityStocksNewsBreaks – Why Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. “The company’s AVERSA(TM) can be incorporated into any transdermal patch and includes aversive agents to prevent misuse and accidental exposure to drugs with abuse potential, specifically opioids. AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia… Nutriband…

TuesdayMay 21, 2024 1:26 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, will be spotlighted in an upcoming webinar, hosted by RedChip Companies. The event is slated for May 30, 2024, and will begin at 4:15 p.m. ET. Nutriband chair Serguei Melnik and CEO Gareth Sheridan will present during the event, which will provide key information for investors regarding current operations and upcoming milestones. To register for the event, visit https://ibn.fm/9REfQ To view the full press release, visit https://ibn.fm/mH9jC About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development…

Site Search

Company Search

Tag: Nutriband Inc. NTRB